Sophiris reports patient death in prostate cancer trial

Sophiris Bio Inc. (NASDAQ:SPHS) lost $1.51 (40%) to $2.24 on Monday after reporting a patient death in an open-label Phase IIb trial evaluating topsalysin

Read the full 245 word article

User Sign In